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TLF and revascularization rates with favorable safety outcomes for
the treatment of small vessels and long lesions through 5 years.
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BACKGROUND Recent study reported that arterial healing of drug
eluting stents was impaired with greater delay at the ﬂow divider
(high shear stress region) as compared with the opposite side of side
branch (SB) (low shear stress region). This study investigated the
differences in neointimal growth on stent struts between thin- and
thick-strut drug eluting stents (DES) implanted in coronary bifurca-
tion lesions by using optical coherence tomography (OCT).
METHODS Sixty-two bifurcation lesions treated with second genera-
tion DES were evaluated with OCT in 51 patients (66.1 y.o) at 6 to 12
months follow-up angiography. The stent strut was deﬁned as thin
when less than 100mm and thick when more than 100mm. Each lesions
were divided into thick-DES (n¼20; Nobori biolimus-eluting stents) or
thin-DES (n¼42; Xience everolimus-eluting stents and Resolute
Integrity zotarolimus-eluting stents). Neointimal coverage was
assessed based on cross-sectional OCT images containing SB at 400mm
interval, and separately evaluated according to three independent
regions: SB ostium (SO), the 1/2 circumference of the vessel wall
opposite to SB (LS; low share stress region), and the vessel wall
adjacent to SB (HS; high shear stress region). Incidence of uncovered
struts and neointimal thickness were measured on the cross sectional
OCT images.
RESULTS Total of 2437 struts were analyzed in this study (thick-DES:
911 vs. thin-DES: 1526). The incidence of uncovered struts was
signiﬁcantly higher at HS region compared with LS regions in thick-
DES (16.8% vs. 7.9%, p<0.01), while there was no signiﬁcant differ-
ence in thin-DES at both HS and LS region (7.3% vs. 5.4%, p¼0.1643).
The incidence of uncovered struts was signiﬁcantly higher in thick-
DES compared with thin-DES at HS region (16.8% vs 7.3%, p<0.01),
while there was no signiﬁcant difference at both LS and SO region
(7.9% vs. 5.4%, p¼0.0846; 34.7% vs. 36.4%, p¼0.7606, respectively).
Neointimal thickness was signiﬁcantly smaller in thick-DES compared
with thin-DES at both HS and LS region (69.446.6mm vs.
99.970.8mm, p<0.01; 72.247.6mm vs. 98.569.5mm, p<0.01,
respectively), while there was no signiﬁcant difference at SO region
(48.731.8mm vs. 48.736.1mm, p¼0.8386).
CONCLUSIONS Thin strut DES was homogeneously endothelialized in
bifurcation lesions and may have more favorable arterial healing
response for bifurcation lesions compared with thick strut DES.
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BACKGROUND Chronic total occlusions (CTO), deﬁned by TIMI 0 ﬂow
and duration of occlusion of more than 3 month, are associated with a
higher risk of restenosis compared to other lesion types. We evaluated
clinical and angiographic results after recanalization of CTOs with the
Sirolimus eluting Orsiro hybrid stent with bioresorbable polymer
coating. Orsiro is a cobalt chromium stent with an absorbable polymer
and thin struts of 60 mm. We compared two consecutive patient series
undergoing recanalization for CTO with either the Orsiro Sirolimus-
eluting stent (O-SES) or a Zotarolimus- eluting stent (ZES)
METHODS 74 patients after successful recanalization of a true CTO in
a native coronary artery where enrolled in our prospective registry
(clinical trials.gov NCT02162082) and compared with 57 patients
treated with a Zotarolimus-eluting stent. In 68 % vs 50% CTO recan-
alization was performed by antegrade and in 32%vs 5% by retrograde
approach. After pre-dilatation a mean of 2.71.3 (range 1-6) Orsiro
stents and 2.71.2 (1-7) ZES were implanted with a mean length of
81.930.6mm. 32.4% (N¼ 24/74) of patients in the Orsiro group suf-
fered from diabetes mellitus and 28.1%(N¼16/57)in the Zotarolimus
group. In 66.2% vs 61.4% CTO was located in RCA, 18.9%vs15.8% in
LCX and in 14.9%vs 22.8% in LAD. Reference diameter post PCI was
3.040.49mm (3.190.56mm), MLD 2.820.51mm (3.060.48mm)
and percent diameter stenosis 7.610.0 (3.78.3). Dual antiplatelet
therapy (DAPT) was recommended for 12 months with aspirin and
clopidogrel. Control angiography was scheduled after 9 and clinical
follow-up after 12 month. The primary angiographic outcome was in-
stent late lumen loss. Secondary angiographic endpoints include
minimal luminal diameter, percentage of diameter stenosis, binary
restenosis. Primary clinical outcome measures were target lesion
revascularization rate (TLR) and major adverse cardiac events (MACE)
deﬁned as composite of cardiac death, myocardial infarction related
to the target vessel and target vessel revascularization.
RESULTS The primary endpoint in-stent late lumen loss was
0.240.53mm for the Orsiro stent compared with 0.590.72mm for
the Zotarolimus stent (p¼0.01), MLD was 1.990.63mm versus
1.870.80mm (p¼0.86), percent diameter stenosis 24.719.2% vs.
27.728.7% (p¼0.58), respectively. TLR was 9.7% for O-SES and 10.5 %
for ZES, resulting in a total MACE rate of 10.8% vs 12.3% (p¼0.79). Of
note, there was no deﬁnite or probable stent thrombosis according to
ARC criteria in both groups within 12 months DAPT treatment.
CONCLUSIONS Treatment of true CTO lesions with the Sirolimus
eluting abluminal coated Orsiro stent resulted in a signiﬁcantly lower
in-stent late lumen loss compared with Zotarolimus eluting stents and
no occurrence of deﬁnite or probable stent thrombosis with a 12
months dual antiplatelet therapy. Clinical results were similar to
Zotarolimus eluting stents.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Chronic total occlusion, Drug-eluting stent, sirolimus
TCT-564
Clinical Predictors of Target Lesion Revascularization after SES or EES
implantation
Seiichi Hiramori,1 Hirotoshi Watanabe,2 Hiroki Shiomi,3 Ken Kozuma,4
Takeshi Morimoto,5 Keiichi Igarashi,6 Kazushige Kadota,7
Kengo Tanabe,8 Yoshihiro Morino,9 Shinichi Shirai,10 Kenji Ando,11
Masakiyo Nobuyoshi,1 Takeshi Kimura12
1Kokura Memorial Hospital, Kitakyushu, Japan; 2Kyoto University
Graduate School of Medicine, Kyoto, Japan; 3Kyoto University
Graduate School of Medicine, Kyoto, NA; 4Teikyo University Hospital,
Tokyo, Japan; 5Hyogo College of Medicine, Nishinomiya, Hyogo;
6Japan Community Health care Organization Hokkaido Hospital,
Sapporo, Japan; 7Kurashiki Central Hospital, Kurashiki, Japan; 8Mitsui
Memorial Hospital, Tokyo, Japan; 9Iwate Medical University, Morioka,
Iwate; 10Kokura Memorial Hospiral, Kitakyushu, Fukuoka; 11Kokura
memorial hospital, Kitakyusyu, Japan; 12Kyoto University, Kyoto,
Japan
BACKGROUND Several studies have performed the comparison of
outcomes between 1st generation drug eluting stent Sirolimus-Eluting
Stent (SES) and 2nd generation drug eluting stent Everolimus-Eluting
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these stents have not been well evaluated.
METHODS We performed additional analysis using data of the Ran-
domized Evaluation of Sirolimus-Eluting Stent Versus Everolimus-
Eluting Stent Trial (RESET trial). In this all-comer prospective multi-
center randomized open-label trial, 3196 patients were randomly
assigned to implant either SES (1600 patients) or EES (1596 patients).
Excluding the lesions where operators failed to implant assigned
stents and which we could not follow for 3 years, we included in
analysis 1666 lesions treated with SES and 1679 lesions with EES.
Primary endpoint of this study was target lesion revascularization
(TLR) within 3 years after index procedure. We detected the inde-
pendent predictors of TLR for each stents using multivariate logistic
regression model instead of Cox’s proportional hazard model because
log minus log curve of any predictor did not prove linearity of hazard
during follow-up. We also analyzed angiographic data of some pa-
tients participating QCA substudy in RESET trial, stratifying important
predictors.
RESULTS In RESET trial, there was no signiﬁcant difference in target
lesion revascularization between the SES and EES groups (7.9% versus
6.6%; P¼0.16). After adjustment for the clinical factors of p<0.1 in
univariate analyses, the following factors were independent pre-
dictors of TLR. In SES group, hemodialysis (odds ratio [OR], 6.36; 95%
conﬁdence interval [CI], 3.17-12.61: p<0.0001) and lowered ejection
fraction <30% (OR, 2.94; 95% CI, 1.06-7.54: p¼0.04) were an inde-
pendent predictor of TLR. On the other hand, in EES group, although
prior PCI (OR, 2.16; 95% CI, 1.37-3.45: p¼0.001), number of stents more
than 2 (OR, 2.14; 95% CI, 1.16-4.06: p¼0.02), ostium lesion (OR, 0.40;
95% CI, 0.14-0.93: p¼0.03), and direct stenting (OR, 0.56; 95% CI, 0.31-
0.97: p¼0.04) were also independent predictors of TLR, hemodialysis
was a strong independent predictor of TLR (OR, 2.70; 95% CI, 1.37-5.11:
p¼0.005). In QCA data, late loss in 8 months follow-up coronary
angiogram were similar after SES or EES implantation in both all
cohort and stratiﬁed groups with hemodialysis or diabetes.
CONCLUSIONS In general, the clinical factors of TLR between SES
and EES were similar. Hemodialysis was a strong clinical predictor of
TLR in both stents.
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BACKGROUND The duration of dual antiplatelet therapy (DAPT) after
Everolimus-eluting stent (EES) implantation is controversial. Short
term of DAPT was recommended, but long term of DAPT has been
reported to be effective. We studied about major adverse cardiac and
cerebral events (MACCE: combined end point of all cause of death,
nonfatal myocardial infarction and cerebral arterial disorder) over the
patients who were free from MACCE during the ﬁrst two years after
EES implantation.
METHODS A total of 1918 patients who underwent successful percu-
taneous coronary intervention (PCI) with EES at 22 centers in Japan
from 2010 through 2011 were enrolled, and 742 patients were followed
over 2 years free from MACCE. We divided these MACCE-free patients
into two groups: those who were prescribed DAPT over 2 years (Over-
2-Year DAPT: n¼591) and those who were not (Under-2-Year DAPT:
n¼151). We compared these two groups about MACCE after 2-year
follow-up with and without baseline adjustment by propensity score
matching (n¼145 in both group). And we studied about bleeding, stent
thrombosis and restenosis.
RESULTS A total of 50 MACCE were observed in this study (Over-2-
Year DAPT, 38; Under-2-Year DAPT, 12, respectively) without signiﬁ-
cant difference (Log-rank test, p¼0.19). Even after baseline adjust-
ment, there were no difference about MACCE (over-2-Year DAPT, 8;
Under-2-Year DAPT, 11, respectively, p¼0.19). In this study, 15 of
major bleeding, 5 of restenosis and 2 of stent thrombosis were
observed after 2-year follow-up, and there were no statistical differ-
ence, although the events numbers were not enough to compare.CONCLUSIONS Continuing DAPT did not prevent MACCE in patients
who were free from MACCE during the ﬁrst two years after ever-
olimus-eluting stent implantation.
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BACKGROUND A patient-level meta-analysis of 5 randomized trials
including 4,896 patients found that the XIENCE cobalt chromium
everolimus drug-eluting stent (DES) signiﬁcantly improved cardio-
vascular (CV) outcomes compared with bare metal stents (BMS) (Val-
gimigli et al., 2014). Using these results, a cost-effectiveness analysis
(CEA) was conducted comparing XIENCE vs. BMS in percutaneous
coronary intervention (PCI).
METHODS The CEA was conducted using a Markov state transition
model with a 2-year time horizon from the U.S. payer perspective. The
base case evaluated lesion-speciﬁc outcomes including CV-related
mortality, target vessel revascularization (TVR), TVR-related
myocardial infarction (MI), and stent thrombosis (ST). Patient-ori-
ented outcomes were evaluated in a one-way sensitivity analysis with
all-cause mortality, TVR, all-cause MI, and ST. Transition probabilities
and risk of clinical events were taken from the Valgimigli 2014 meta-
analysis. Resource use and unit costs (2015 USD) from the published
literature were included for index PCI with XIENCE or BMS, TVR,
MI, and dual antiplatelet therapy (DAPT). Quality of life impacts (i.e.,
health utilities) from the published literature were included for cor-
onary artery disease (CAD), MI, and TVR.
RESULTS The lesion-speciﬁc base-case analysis found that XIENCE
was more effective and less costly than BMS, resulting in an additional
0.018 quality-adjusted life years (QALYs) and a cost savings of $236
per patient. The patient-oriented sensitivity analysis provided similar
results that XIENCE was more effective and less costly than BMS,
resulting in an additional 0.013 QALYs and a cost savings of $288 per
patient. Results were robust to the majority of sensitivity analyses,
only being sensitive to pricing for clopidogrel ($9,755 per QALY). The
probabilistic sensitivity analysis predicted that XIENCE was associ-
ated with a 99.5% chance of being cost saving or cost-effective vs.
BMS at a cost per QALY threshold of $50,000.
CONCLUSIONS Previous studies assessing cost-effectiveness of DES
vs. BMS have shown mixed results which may be due to the clinical
performance of earlier generation DES. Utilizing data from a high-
quality, patient-level meta-analysis, our study clearly demonstrated
that XIENCE is an economically attractive strategy compared to BMS
for PCI.
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BACKGROUND TARGET I randomized controlled trial (RCT) aimed to
compare the safety and effectiveness of an abluminal groove-ﬁlled
biodegradable polymer sirolimus-eluting stent (FIREHAWK, Micro-
Port Medical, Shanghai, China) with a cobalt-chromium everolimus-
eluting stent (CoCr-EES) XIENCE V for the treatment of single de novo
